Company intelligence / Profile preview

Javelin Pharmaceuticals

Cambridge, Massachusetts, United Statesjavelinpharmaceuticals.com ↗

Ownership: Private
Development stage: NDA

Overview

Javelin developed differentiated acute pain control drugs with improved safety profiles and novel delivery methods. Its lead product Dyloject™ (injectable diclofenac) was approved in Europe; Ereska™ (intranasal ketamine) and Rylomine™ (intranasal morphine) were in advanced clinical trials at the time of acquisition. Clinical data showed rapid onset of action with reduced side effects for intranasal formulations

Therapeutic areas: OtherNeurology
Modalities: Small moleculesnovel drug formulations
Industry: Biotech

Drug pipeline

2 assets

Dyloject

NDA

Indications: Post-operative pain

1 more asset in the full pipeline.

Partnerships

No major disclosed pharma partnerships pre-acquisition; investors included Hospira as strategic partner/investor before full acquisition

Beyond the preview

Go deeper on Javelin Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Javelin Pharmaceuticals.